Teriflunomide Tablet, Film Coated
Product Images NDC 70377-017

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Teriflunomide (NDC 70377-017). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Biocon Pharma Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel- 7 mg Tablet Sleeve (7mg Sleeve)

Packaging label for Teriflunomide Tablets 7 mg by Biocon Pharma Inc. The label indicates the dosage form as film-coated tablets, with a package containing 28 tablets. It includes the NDC number 70377-017-91, directions for opening the blister pack, and dispensing instructions.*

FDA Label Image

Principal Display Panel- 7 mg Tablet Bottle (Bottle7s)

Label for Teriflunomide Tablets 7 mg, film-coated oral tablets by Biocon Pharma Inc. The label shows the NDC 70377-017-11 and indicates a package containing 30 tablets. It includes dosage information, storage instructions, and manufacturer details for Biocon Pharma Inc. in New Jersey and Biocon Pharma Limited in Bengaluru, India.*

FDA Label Image

Chemical Structure (Teriflunomide 01)

Chemical structure of teriflunomide, the active ingredient in the drug Teriflunomide. The structure includes a trifluoromethyl-substituted phenyl ring connected to an amide and carboxylic acid functional groups.*

FDA Label Image

Figure 1 (Teriflunomide 02)

Kaplan-Meier plot showing the percentage of disability progression sustained over 12 weeks in patients treated with placebo, 7 mg teriflunomide, and 14 mg teriflunomide. The x-axis represents the duration in weeks up to 108 weeks, while the y-axis shows the percentage of sustained disability progression. The graph includes a table of the number of patients at risk across time points for each group. Statistical significance is noted between 14 mg and placebo.*

FDA Label Image

Figure 2 (Teriflunomide 03)

A line graph showing disability progression sustained over 12 weeks in percentage on the y-axis and weeks on the x-axis up to 108 weeks. The graph compares three groups: Placebo, 7 mg Teriflunomide, and 14 mg Teriflunomide. It includes a number at risk table for each group at various time points below the x-axis. The 14 mg Teriflunomide group shows statistically significant lower disability progression compared to placebo (*p < 0.05).*

FDA Label Image

Principal Display Panel (7 mg Tablet Carton)

The packaging label for Teriflunomide Tablets 7 mg oral film-coated tablets by Biocon Pharma Inc. The carton indicates a 28-tablet count with the NDC 70377-017-91. Instructions for opening the blister card and storage conditions are also included on the label along with manufacturer details for Biocon Pharma Limited in India.*

FDA Label Image

Principal Display Panel- 7 mg Tablet Blister (Teriflunomide 05)

Teriflunomide Tablets 7 mg film-coated oral tablets packaging label by Biocon Pharma Inc. The carton indicates 28 tablets with Rx only status. The label includes a blister pack diagram labeled with days for daily dosing and storage instructions. The NDC is 70377-017-91.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.